Plasmodium vivax clinically resistant to chloroquine in Colombia.

J Soto Consorcio de Investigaciones Bioclínicas, Bogotá, Colombia. JSoto@elsitio.net.co

Search for other papers by J Soto in
Current site
Google Scholar
PubMed Close
,
J Toledo Consorcio de Investigaciones Bioclínicas, Bogotá, Colombia. JSoto@elsitio.net.co

Search for other papers by J Toledo in
Current site
Google Scholar
PubMed Close
,
P Gutierrez Consorcio de Investigaciones Bioclínicas, Bogotá, Colombia. JSoto@elsitio.net.co

Search for other papers by P Gutierrez in
Current site
Google Scholar
PubMed Close
,
M Luzz Consorcio de Investigaciones Bioclínicas, Bogotá, Colombia. JSoto@elsitio.net.co

Search for other papers by M Luzz in
Current site
Google Scholar
PubMed Close
,
N Llinas Consorcio de Investigaciones Bioclínicas, Bogotá, Colombia. JSoto@elsitio.net.co

Search for other papers by N Llinas in
Current site
Google Scholar
PubMed Close
,
N Cedeño Consorcio de Investigaciones Bioclínicas, Bogotá, Colombia. JSoto@elsitio.net.co

Search for other papers by N Cedeño in
Current site
Google Scholar
PubMed Close
,
M Dunne Consorcio de Investigaciones Bioclínicas, Bogotá, Colombia. JSoto@elsitio.net.co

Search for other papers by M Dunne in
Current site
Google Scholar
PubMed Close
, and
J Berman Consorcio de Investigaciones Bioclínicas, Bogotá, Colombia. JSoto@elsitio.net.co

Search for other papers by J Berman in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.4269/ajtmh.2001.65.90
Volume/Issue:
Volume 65: Issue 2
Page(s):
90–93
Restricted access
Get Permissions

Chloroquine-resistant Plasmodium vivax has been the subject of numerous case reports and prospective studies from Oceania and Asia. In contrast, only case reports exist from the Americas. We performed a prospective study with 28-day follow-up of clinical responses to chloroquine in 2 P. vivax-endemic regions of Colombia. Three (11%) of 27 patients failed to respond to treatment with the standard regimen of chloroquine (1,500 mg of base over 3 days). One patient demonstrated RI resistance on Day 26; one patient demonstrated RI resistance due to recrudescence of blood stages on Day 11; and one patient demonstrated RII resistance of blood stages by never displaying clearing of peripheral parasitemia. All patients were successfully treated with primaquine, which has some blood stage efficacy against P. vivax, combined with a second course of chloroquine. Clinical resistance of P. vivax to chloroquine is present in Colombia and should be monitored in the Americas.

Author Notes

Published Online:
Aug 2001
Cover The American Journal of Tropical Medicine and Hygiene
The American Journal of Tropical Medicine and Hygiene
Print ISSN:
0002-9637
Past two years Past Year Past 30 Days
Abstract Views 759 651 47
Full Text Views 363 18 1
PDF Downloads 132 21 3
 

 

 

 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save